![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Glecaprevir/pibrentasvir & sofosbuvir for 16 weeks without ribavirin is safe and highly effective retreatment for patients who have failed an
NS5A inhibitor containing antiviral regimen
|
|
|
EASL 2022 June 22-26 London
Edward J. Gane1, Bridget Faire2, Sherine Helmy3, James Freeman4. 1University of Auckland, Grafton Campus, Liver Unit, Auckland, New Zealand; 2New Zealand Liver Transplant Unit-Ward 71, Auckland, New Zealand; 3Pharco Corporation, Cairo, Egypt; 4GP2U, Australia
![0626221](../images/062722/062722-3/0626221.gif)
![0626222](../images/062722/062722-3/0626222.gif)
![0626223](../images/062722/062722-3/0626223.gif)
![0626224](../images/062722/062722-3/0626224.gif)
![0626225](../images/062722/062722-3/0626225.gif)
![0626226](../images/062722/062722-3/0626226.gif)
![0626227](../images/062722/062722-3/0626227.gif)
![0626228](../images/062722/062722-3/0626228.gif)
![0626229](../images/062722/062722-3/0626229.gif)
![ReplaceHalf10](../images/062722/062722-3/ReplaceHalf10.gif)
![06262211](../images/062722/062722-3/06262211.gif)
![06262212](../images/062722/062722-3/06262212.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|